Several studies have suggested that local hepatic ACE2 overexpression and blockers of AngII and ATR1 can be used in the prevention and treatment of diabetes, insulin resistance, glucose homeostasis, hepatic steatosis, NAFLD, liver fibrosis and other metabolic disorders [2,16,33,34,39,40]. The gene discussed is ACE2; the disease is fatty liver disease.